Tan Xinrui, Wu Xiaochuan, Chen Jie, Wu Yan, Li Shijun, Chen Xianmei, Zhang Xingxing
Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
J Pediatr Endocrinol Metab. 2019 Jan 28;32(1):85-88. doi: 10.1515/jpem-2018-0266.
Background Aromatase excess syndrome (AEXS) is a rare autosomal dominant disorder caused by CYP19A1 overexpression. Clinical manifestations of AEXS include pre- or peri-pubertal gynecomastia, advanced bone age and compromised adult height. Case presentation Here we report an 8-year-old boy diagnosed with AEXS by chromosomal array that revealed a 1.1 Mb novel de novo duplication at 15q21.2, with a predicted final height of 157.4 cm. We prescribed letrozole and growth hormone (GH) to maximize his linear growth. Without further bone age advancement, his height increased from 137.7 cm to 144 cm after an 8-month treatment period. Conclusions We identified a novel duplication at 15q21.2 in AEXS, and found that aromatase inhibitor (AI) plus GH might provide a better growth-promoting approach for AEXS patients.
芳香化酶过剩综合征(AEXS)是一种由CYP19A1过度表达引起的罕见常染色体显性疾病。AEXS的临床表现包括青春期前或青春期乳腺增生、骨龄提前和成人身高受损。病例报告:在此,我们报告一名8岁男孩,通过染色体阵列诊断为AEXS,该阵列显示15q21.2处有一个1.1 Mb的新发重复,预测最终身高为157.4 cm。我们开了来曲唑和生长激素(GH)以最大限度地促进他的线性生长。在没有进一步骨龄进展的情况下,经过8个月的治疗期,他的身高从137.7 cm增加到了144 cm。结论:我们在AEXS中鉴定出15q21.2处的一个新重复,并发现芳香化酶抑制剂(AI)加GH可能为AEXS患者提供更好的促进生长方法。